{"chunk_id": "medquad__chunk_3796", "source": "medquad", "text": "metrial cancer. In postmenopausal women with osteoporosis (decreased bone density), raloxifene lowers the risk of breast cancer for women who have a high or low risk of breast cancer. It is not known if raloxifene would have the same effect in women who do not have osteoporosis. Talk with your doctor about the risks and benefits of taking this drug.     Other SERMs are being studied in clinical trials.          Aromatase inhibitors and inactivators      Aromatase inhibitors (anastrozole, letrozo"}